Nathan Rice

Stock Analyst at Piper Sandler

(3.05)
# 1,233
Out of 5,241 analysts
64
Total ratings
50%
Success rate
11.24%
Average return

Stocks Rated by Nathan Rice

First Mid Bancshares
May 1, 2026
Reiterates: Overweight
Price Target: $52$55
Current: $42.10
Upside: +30.64%
Byline Bancorp
Apr 27, 2026
Maintains: Overweight
Price Target: $37$40
Current: $32.24
Upside: +24.07%
Bank First
Apr 20, 2026
Maintains: Neutral
Price Target: $150$157
Current: $141.80
Upside: +10.72%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $44.75
Upside: -6.15%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $97.56
Upside: -24.15%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $137.47
Upside: -38.90%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $159.77
Upside: +23.30%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $21.02
Upside: -57.18%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $535.90
Upside: -18.83%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $292.68
Upside: -20.39%
Initiates: Neutral
Price Target: $83
Current: $58.74
Upside: +41.30%
Initiates: Overweight
Price Target: $15
Current: $20.56
Upside: -27.04%